Key Presentations on Myelodysplastic Syndrome From ASH 2020

Harry P. Erba, MD, PhD


December 28, 2020

Dr Harry Erba from Duke University reviews several key studies on myelodysplastic syndrome (MDS) presented at the 2020 American Society of Hematology annual meeting.

Dr Erba highlights a multicenter biologic assignment trial comparing reduced-intensity allogeneic hematopoietic stem cell transplantation (HSCT) vs hypomethylating therapy or best supportive care in patients age 50-75 with advanced MDS.

The study showed a 21% improvement in 3-year overall survival in patients who underwent HSCT compared with those who received hypomethylating therapy or supportive care.

Dr Erba also reports on a randomized phase 2 study evaluating the efficacy and safety of pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS.

The event-free survival of patients treated with pevonedistat and azacitidine was superior to that of patients treated with azacitidine alone. There was also a trend for improvement in overall survival.

Finally, Dr Erba discusses the results of a phase 1b study of the anti-TIM-3 monoclonal antibody sabatolimab, or MBG453, in combination with hypomethylating agents in patients with high-risk MDS.

In these patients with high-risk and very high-risk MDS, the overall response rate was 64%. The complete remission rate was only 23% and, according to Dr Erba, was similar to what might be expected with azacitidine alone.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.